Target therapy for lung cancer Turkey
Last updated: 8/16/2024
Target therapy for lung cancer in Turkey: Our Best Clinics and Costs 2024
5 Recent Target therapy for lung cancer Reviews in Turkey: Check Real Patient Experience
Salim Brahmi • Lung cancer Algeria Dec 13, 2018
Profesional staff,
Роман • Lung cancer Russian Federation Nov 13, 2018
Елена • Lung cancer Kazakhstan Jul 21, 2018
Аziz • Lung cancer Turkey Mar 8, 2024
Target therapy for lung cancer Overview in Turkey
Takeaways
Related procedures & Costs
How it works
What to expect
Benefits
Payment
Surgery Time - 2
hours
Stay in the country -
7
days
Rehabilitation - 1
day
Anesthesia - Local anesthesia
Requests processed - 46119
Bookimed fees - $0
Types of Lung cancer surgery
- Lobectomy - from $7000
The procedure involves removing a lung lobe, typically to treat conditions like lung cancer, improving patient health.
- Lung cancer surgery - from $17000
The procedure removes tumors in the lungs, aids with diagnosis, and generally alleviates symptoms and prolongs life.
- Wedge Resection - from $8500
This surgery removes a small, wedge-shaped part of lung tissue, primarily to treat localized lung cancer.
- Pneumonectomy - from $1200
The operation removes an entire lung to treat lung diseases, enhancing breathing capacity and overall health.
-
The operation simultaneously removes lung and liver tumors, reducing time and resources while improving patient recovery.
- Lung segmentectomy - from $9000
This surgery removes lung segments harboring cancerous cells, protecting healthy tissue.
How to find best solution with Bookimed?
Check available options for your case on the website.
Request a free consultation with documents assessment.
Download your medical records and describe your needs.
Receive customized free treatment plans with prices and details.
Compare them and finalize your choice.
Agree the date for your upcoming clinic visit.
Arrive and pay at the clinic. Bookimed fees are $0 for you.
From start to finish, the Bookimed coordinator keeps you safe and comfortable during your medical journey.
💚Your benefits with Bookimed
100% free, non-binding assessment of your medical records
Instant FREE personalized treatment plans to make the right choice
Expert guidance in choosing the perfect Oncology doctor and clinic.
Special packages and exclusive prices for our patients.
24/7 Bookimed guidance at no cost, guaranteed.
Hassle-free translation of your medical documents for clinics.
Bookimed's multilingual team ensures comfortable communication.
Bookimed ensures transparent and secure payments. Patients pay at the clinic with no additional fees.
Available Payment Methods:
How to Secure an Appointment:
- Documents: Passport and ticket copies.
- or
- Deposit:
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
For more information, see our
Payment Policy
Step-by-Step Roadmap
Day 1 - Arrival
- Arrive at the medical facility.
- Complete necessary paperwork and registration procedures.
Day 2 - Pre-Operation
- Consultation with an oncologist and pulmonologist.
- Undergo physical examination and laboratory tests.
- Perform imaging studies like CT or MRI.
Day 3 - Preparing for Target Therapy
- Review of medical history and test results.
- Explanation of the target therapy procedure and its risks.
- Signing of consent forms.
Day 4 - Target Therapy
- Administration of target therapy drugs orally or through IV.
- The process lasts a few hours, no anesthesia required.
- The therapy targets specific genes and proteins of cancer cells.
Day 5 - Post-Operation
- Regular monitoring of vital signs and side effects.
- Stay in the clinic for observation for a day.
Week 1 - Rehabilitation
- Follow-up consultation with oncologist.
- Regular blood tests and imaging studies to monitor progress.
Week 2-4 - Rehabilitation
- Continuation of target therapy at home if advised by the doctor.
- Gradual return to work and daily activities.
Month 2-3 - Final Result
- Complete recovery and return to regular lifestyle.
- Regular check-ups to monitor cancer status.
Please note that the recovery process can vary depending on individual health conditions and how the body responds to the treatment.
How Much Does Target therapy for lung cancer Cost in Turkey?
The average price of Target therapy for lung cancer in Turkey is $7100, the minimum price is $2500, and the maximum price is $11700.
| Turkey | Austria | Spain | |
|---|---|---|---|
| Target therapy for lung cancer | from $2500 | - | from $3129 |
| The total cost is calculated individually. It may range depending on your medical issue, doctor's qualification, procedure complexity and related complications (if they occur). You’ll get the exact price for a plastic surgery procedure after a consultation with a doctor. | |||
Below average
Above average
No-Cost Review of Your Target therapy for lung cancer Medical Records
Upload Your Medical Records
Get Rapid Translation for Free
Receive Personalized Recommendations
Discover the Best Target therapy for lung cancer Clinics in Turkey: 5 Verified Options and Prices
Check the hospital ranking based on requests and 5 reviews to pick the right Target therapy for lung cancer clinic for you.
Highest-Rated Clinic for Target therapy for lung cancer
Turkey,
Istanbul
Anadolu Medical Center is a multidisciplinary facility providing American treatment standards at affordable prices in Istanbul (Turkey). Anadolu affiliates with the Johns Hopkins Hospital, one of the best medical facilities in the USA.
Oncology, hematology oncology, urology, neurosurgery, women's health, , and check-up are the leading specialties in Anadolu Hospital.
The medical center is among the Top 10 hospitals in the world according to the Medical Travel Quality Alliance (MTQUA), an international organization that promotes excellent standards of health services for medical tourists.
Patients from the United States, the United Kingdom, Romania, Bulgaria, and Azerbaijan choose Anadolu Medical Center.
Summary about Anadolu from patients' reviews:
The Anadolu Clinic is a highly-regarded medical facility located on the coast of the marble sea. It is renowned for its professionalism, cleanliness, and attention to detail. The staff is polite, attentive, and responsive to patients' needs. Highly-trained and skilled doctors are available for comprehensive examinations and treatments, and the recovery room is bright and comfortable with a beautiful view. Patients have benefited from the services of an excellent translator, Elmira, and the support of coordinators Zakhida, Bakhtygul, and Amina, Gayana. The clinic also offers a transfer service from the airport to the hotel and back, as well as booking a hotel conveniently located 10-15 minutes away. Anadolu is the perfect choice for a successful treatment and recovery.
Top 5 Anadolu Advantages:
- Highly skilled and experienced medical staff
- Advanced equipment
- Personal coordinators and interpreters
- Pleasant atmosphere
- Wide range of medical services and treatments
Read more details
accreditations:
+5
Anonymous
• Oct 4, 2023
Hello, I am from Uzbekistan, from Tashkent, many thanks to Bookimed, when we didn’t know where to turn, where to find a good clinic, they helped me choose a very good clinic and the doctors talked to the patients themselves, they were all happy with the treatments, I have never seen an unhappy patient.
Prices:
| Target therapy for lung cancer | $2500 - $11700 |
Clinic
Prices
Reviews
Turkey,
Bursa
Private Medicabil Hospital is a private multi-specialty medical center in Bursa, Turkey. The team is dedicated to neurosurgery, orthopedics, weight loss surgery, and medical check-ups. Among the clinic's achievements are the success rates:
- 99,9% for hip replacement;
- 99,9% for MAKOplasty total hip replacement;
- 99,9% for total knee replacement (arthroplasty) revision.
Private Medicabil Hospital serves both adults and children. 215508 patients choose Private Medicabil Hospital to get medical care every year. Patients from the Balkans, Arab League states, and Russian-speaking countries visit the clinic most often.
Read more details
accreditations:
Price
upon request
Clinic
Turkey,
Istanbul
Emsey Hospital, one of Turkey's multi-specialty private medical centers, provides health services at the A+ class level hospital. The hospital has ISO and JCI accreditations as a reliable medical center. The facility offers general, surgical, and internal medicine treatments as a general hospital. Emsey Hospital has provided healthcare services to patients worldwide since 2012. The hospital's Advanced Spine Surgery Center performs congenital and complicated orthopedic treatments, from scoliosis to spine fusion surgeries. The Bone Marrow Transplantation Unit is one of the largest units in Turkey, with 45 beds.
Read more details
accreditations:
+2
Дурдона
• Nov 13, 2021
We liked Emsey clinic very much. we were met from the airport with an interpreter and a driver. then placed in a very good hotel. delicious food was served 2 times at the hotel. The hotel had spacious comfortable rooms with all amenities. On the 1st day we were brought for analysis, on the 2nd day they made a diagnosis, started treatment and we were placed in a ward. Within 5 days, we received the necessary treatment and good service. The doctors were very skilled and experienced. The coordinator Janseit was with us for 1 week and was very helpful in creating all the necessary amenities for us. Thanks to all the staff at Emsey Clinic.
Price
upon request
Clinic
Reviews
We're rated “Excellent” on TrustPilot
At Bookimed, we put your health first with safe and easy solutions. Our quality care is proven by excellent reviews from patients.
Turkey,
Istanbul
accreditations:
Дмитрий
• Jan 22, 2022
Everything went well! I liked the clinic!
Price
upon request
Clinic
Reviews
Turkey,
Istanbul
Istanbul Oncology Hospital is a private multi-specialty medical center located in Istanbul, Turkey. Istanbul Oncology Hospital, established in 2008, started as an outpatient oncology clinic and later expanded to become a fully-fledged Oncology Hospital in 2015. The team is dedicated to orthopedics, oncology, diagnostics, and medical check-up. Istanbul Oncology Hospital serves only adults. At Istanbul Oncology Hospital, all procedures and medical interventions are carried out by experienced medical staff guided by advanced technology. 11640 patients choose Istanbul Oncology Hospital to get medical care every year. Patients from Russian-speaking countries, Europe & Commonwealth, and the Balkans often visit the clinic.
Read more details
accreditations:
Aline
• Apr 15, 2024
I felt very comfortable and very well cared for. And everybody treated me so well. So much better than in San Francisco.
I also liked that I got direct answers to all my questions.
Price
upon request
Clinic
Reviews
Your Medical Travel Guide: Essential Tips and Advice
question
explanation
How many days do I need to stay in Turkey?
7 days
Our Doctors
Hisar Intercontinental Hospital
Mustafa Solak, M.D., who was born in 1978, was graduated from School of Medicine, Hacettepe University. He completed his residency education in İstanbul Sisli Etfal Teaching and Research Hospital and completed his fellowship in Cancer Institute of Hacettepe University.
He has dealt with many cases of Breast Cancer, Testicular Cancer, Ovarian Cancer, Lung Cancer, Head-Neck Cancer, Gastrointestinal Cancers.
FIELDS OF MEDICAL INTEREST
Breast cancer
Testicular Cancer
Ovarian Cancer
Lung Cancer
Head & Neck Cancers
Gastrointestinal cancers
EDUCATİON:
Bachelor's: Hacettepe University Faculty of Medicine
Specialization: Istanbul Sisli Etfal Training and Research Hospital
Minor Specialization: Hacettepe University Cancer Institute
INSTITUTIONS WHERE EDUCATION AND WORKED
The University of Texas MD Anderson Cancer Center
Hitit University Corum Training Hospital
Medical Park Hospital
Read more
accreditations:
PROFESSIONAL EXPERIENCE2011-2012Erzurum Koprukoyu State HospitalDepartment: General Medicine2012-2017Istanbul University Cerrahpaşa Medical FacultyDepartment: Internal Medicine06/2017-10/2017Istanbul Gaziosmanpasa Taksim Training and Research HospitalDepartment: Internal Medicine10/2017-11/2018Istanbul University Istanbul Medical FacultyDepartment: Allergy and Immunology Fellowship2018/2022Istanbul University Oncology InstituteDepartment: Medical Oncology Fellowship2022-2023Tekirdag City HospitalDepartment: Medical Oncology Specialist2023-presentIstanbul Medipol University Medipol Bahcelievler Private HospitalDepartment: Medical Oncology Assoc. Prof. EDUCATION2005-2011Medical EducationSivas Cumhuriyet University Medical Faculty, Sivas, Turkey2012-2017Internal MedicineIstanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey2017-2018Allergy-Immunology FellowshipIstanbul University Istanbul Medical FacultyDepartment of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey2018-2022Medical Oncology FellowshipIstanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey2022ESMO Board Certification in Medical Oncology10th September 2022 in Paris, France.2023Medical Oncology Assoc. Prof.Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey INTERNATIONAL CLINICAL TRIALS:1. Astefania - ROCHETitle: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyRole: Subinvestigator2. PFİZERTitle: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLCRole: Subinvestigator3. RECITE - AMGENTitle: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal CancerRole: Subinvestigator4. NAVIGATE - BAYERTitle: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsRole: Subinvestigator5. RUBY - Tesaro (PRA)Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial CancerRole: Subinvestigator6. ENGOT-ov43/GOG-3036 - MSDTitle: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)Role: Subinvestigator7. ASTRA ZENECATitle: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.Role: Subinvestigator8. ROSY-O - ASTRA ZENECATitle: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibRole: Subinvestigator INTERNATIONAL PUBLICATIONSI. Published journal articles indexed by SCI, SSCI, and AHCIWeekly Paclitaxel in Classic Kaposi SarcomaAuthors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.Journal: Medicine, 102(5)Carboplatin Desensitization in Ovarian CarcinomaAuthors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.Journal: Medicine, 101(45), e31726High-Dose Chemotherapy for Ewing’s SarcomaAuthors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.Journal: Medicine, 101(49), e32213Multidrug Refractory TFE3(+) Renal Cell CarcinomaAuthors: Paksoy, Nail, et al.Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221Crizotinib Efficacy in NSCLC with MET AlterationsAuthors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.Journal: Medicine, 101(50), e32368Clinicopathological Features in ALK Mutant NSCLCAuthors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.Journal: Medicine, 101(34)PSMA-Based Tumor Burden in Prostate CancerAuthors: HAS SIMSEK, Duygu, et al.Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690Atezolizumab in Metastatic Urothelial CarcinomaAuthors: TURAL, Deniz, et al.Journal: European Urology Focus, 2021, 7.5: 1061-1066Pulmonary Sarcomatoid CarcinomaAuthors: FERHATOGLU, Ferhat, et al.Journal: Oncology Research and Treatment, 2021, 44.11: 590-601Prognostic Factors in Atezolizumab-Treated Urothelial CarcinomaAuthors: TURAL, Deniz, et al.Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513Atezolizumab with Chemotherapy in Small Cell Lung CancerAuthors: GÜRBÜZ, Mustafa, et al.Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic CancerAuthors: AY, Seval, et al.Journal: Journal of Chemotherapy, 2022, 1-7Trastuzumab Emtansine in Older HER2-Positive Breast Cancer PatientsAuthors: CIL, Ibrahim, et al.Journal: Tumori Journal, 2022, 108.1: 19-25Real-Life Efficacy of Osimertinib in Advanced NSCLCAuthors: HIZAL, Mutlu, et al.Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508ALK-Positive Cells Percentage and Alectinib EfficacyAuthors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148Real-World Data on Alectinib in ALK-Positive NSCLCAuthors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.Journal: Future Oncology, 18(23), 2573-2582Prognostic Factors in Metastatic RCC with T790M MutationAuthors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsFLOT Regimen in Metastatic Gastric CancerAuthors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.Journal: Journal of Cancer Research and TherapeuticsDesensitization Protocol in Lenalidomide Hypersensitivity ReactionsAuthors: DEMIR, Semra, et al.Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397Factors Associated with Diagnostic Skin Test Positivity in PPI HypersensitivityAuthors: ÖZDEMIR, Seçil Kepil, et al.Journal: Allergy, 2019, 74.6: 1187-1190Efficacy of Capecitabine and Temozolomide in Neuroendocrine TumorsAuthors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.Journal: The Oncologist, oyad257Subsequent Treatments in Hormone-Positive Breast Cancer ProgressionAuthors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.Journal: BMC cancer, 23(1), 192Termination of Trastuzumab in HER2-Positive Metastatic Breast CancerAuthors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.Journal: Scientific Reports, 13(1), 8779Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast CancerAuthors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.Journal: Journal of Cancer Research and Clinical Oncology, 1-9Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast CancerAuthors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.Journal: European Journal of Breast Health, 19(2), 128Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast CancerAuthors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.Journal: Future Oncology, 19(10), 727-736Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma PatientsAuthors: Dogan, I., Paksoy, N., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsSingle-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma PatientsAuthors: Dogan, I., Paksoy, N., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsOutcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain MetastasesAuthors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsFLOT Regimen in First-Line Treatment of Metastatic Gastric CancerAuthors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.Journal: Journal of Cancer Research and TherapeuticsPrognostic Factors of Perioperative FLOT Regimen in Operable Gastric CancerAuthors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.Journal: [Not specified]Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi SarcomaAuthors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.Journal: Medicine, 102(39), e35383Comparison of Second-Line Treatments in Metastatic Renal Cell CarcinomaAuthors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.Journal: Medicine, 102(41), e35245Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGYPredictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of PulmonologyLaterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye Thesis:Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combinationAuthors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group studyAuthors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancerAuthors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)Efficacy of temozolomide in pretreated patients with metastatic sarcomaAuthors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumorsAuthors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcomaAuthors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastasesAuthors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinomaAuthors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk studyAuthors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiencesAuthors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)
Read more
Updated: 3/8/2024
The content accuracy and quality have been checked by Bookimed Medical Advisory Board
This page may feature information relating to various medical conditions, treatments, and healthcare services available in different countries. Please be advised that the content is provided for informational purposes only and should not be construed as medical advice or guidance. Please consult with your doctor or a qualified medical professional before starting or changing medical treatment.
5 Recent Target therapy for lung cancer Reviews in Turkey: Check Real Patient Experience
All reviews are checked by Bookimed team to ensure they are real. Clinics or doctors cannot add, edit, or delete reviews.
Bookimed editorial policy
Bookimed, a leading global medical tourism platform, is committed to helping clients looking for Target therapy for lung cancer by offering expert assistance and trustworthy medical solutions for every situation. Smart automatic ranking system is used to compose transparent clinic listings, meticulously maintained by a data scientist using AI for accuracy. The platform guarantees authenticity by publishing reviews from real patients after their treatments. Bookimed offers comprehensive medical solutions, with updates from clinics to ensure trustworthiness. The content about Target therapy for lung cancer, crafted by experienced medical authors and reviewed by specialists, adheres to Bookimed"s Editorial Guidelines, reflecting the platform"s commitment to delivering high-quality and clear health information. For more details or inquiries, feel free to contact us at marketing@bookimed.com or learn more about us and our mission here.
Bookimed CEO Quality Assurance